EVO
Evotec SE
NASDAQ · Healthcare · Drug Manufacturers - Specialty & Generic · DE
$1.60
−4.19%Price chart
Aug 19Aug 24Aug 27Sep 1Sep 4Sep 10Sep 15Sep 18
Key dataSep 18, 2026
Open$1.74
From 52W high−61.45%
Volume1.36M
Market cap$568.62M
P/E (TTM)—
P/S (TTM)0.7x
Div yield—
Key dataSep 18, 2026
Open
$1.74
From 52W high
−61.45%
Volume
1.36M
Market cap
$568.62M
ValuationView details →
P/E (Fwd)
—
EV/EBITDA
−5.9x
P/E (TTM)
—
RSI (14)
30.9
MomentumView details →
1D Return
−4.19%
YTD Return
−46.75%
SummaryUpdated Jun 1, 2026
Evotec SE (NASDAQ:EVO) is a German drug discovery and development company founded in 1993 and headquartered in Hamburg. Originally incorporated as Evotec AG, the company changed its name to Evotec SE in April 2019 and went public in 2004. Evotec operates as a strategic partner to pharmaceutical and biotechnology companies worldwide, providing integrated drug discovery services and biologics manufacturing capabilities. The company has evolved from a traditional contract research organization into a technology-driven platform that combines advanced scientific capabilities with manufacturing expertise to accelerate drug development across multiple therapeutic areas.
Similar companies
Latest newsMore news →
Evotec SE initiated a Phase 1 clinical trial for JST-018, a cocktail of investigational monoclonal antibodies targeting orthopoxviruses, developed by its subsidiary Just - Evotec Biologics under the U.S. Department of War's Accelerated Antibodies Program.11d agoEvotec SE and Plectonic Biotech announced a research collaboration to explore a novel immunotherapy approach for solid tumors, combining Evotec's BiTco costimulatory CD2 bispecifics platform with Plectonic's LOGIBODY® technology.18d ago